Company intelligence / Profile preview

Abionic

Epalinges/Lausanne, Switzerlandabionic.com ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

Abionic has developed the abioSCOPE, an ultra-fast point-of-care diagnostic device using proprietary nanofluidic biosensor technology. Its flagship test detects pancreatic stone protein to identify sepsis risk up to three days earlier than standard methods. The system also supports rapid testing for COVID‑19, iron deficiency, and respiratory allergies. Clinical evidence shows that the PSP test can provide actionable results within five minutes from a finger-prick blood sample at the bedside or in primary care settings.

Therapeutic areas: HematologyImmunologyInfectious Diseases
Modalities: Device (diagnostic platform)Nanofluidic technology-based diagnosticsBiosensor-based diagnostics
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Abionic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abionic.

Explore the full profile